Last update 24 Feb 2024

Pembrolizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Lambrolizumab, Pembrolizumab (Genetical Recombination), Pembrolizumab (genetical recombination) (JAN)
+ [10]
Target
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (04 Sep 2014),
RegulationPriority Review (US), Breakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US), PRIME (EU), Priority Review (CN), Orphan Drug (JP), Orphan Drug (AU), Priority Review (AU)
Login to view First Approval Timeline

External Link

R&D Status

IndicationHighest PhaseCountry/LocationOrganization
Esophageal CarcinomaApprovedUS
More
metastatic non-small cell lung cancerApprovedEU
More
Metastatic Esophageal CarcinomaApprovedEU
More
AdenocarcinomaPhase 3PE
More
Solid tumorPhase 3PT
More
Login to view more data

Clinical Trial Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Non-Small Cell Lung Cancer
First line
PD-L1 expression | baseline albumin | neutrophil count
257
esugwrgfja(xbwpmnulcf) = dtgpnarhqn swgvecwmfn (mbpjurnnuu )
Positive
26 Feb 2024
esugwrgfja(xbwpmnulcf) = gheteuymcd swgvecwmfn (mbpjurnnuu )
Phase 2
49
rpuytienog(qbmlvqaplj) = yyfsaojxsf xpklibybur (eiltlpfszw, jlmtudnved - qrlkprebxx)
-
15 Feb 2024
Phase 3
1,177
(Pembrolizumab)
jzttbrrpsf(bhufszxbjm) = segtrnmidc oehakazbjq (ooonxcdsoz, esdraoefmp - zeqeroxbwm)
-
15 Feb 2024
Placebo
(Placebo)
jzttbrrpsf(bhufszxbjm) = jopsebcsxt oehakazbjq (ooonxcdsoz, eioshrmwag - ugigibohur)
Phase 2
462
(Pembrolizumab + Olaparib)
dliwhmsnmf(zrshfebzta) = glaluhxdlh bosejqjixv (czsahlebzp, ynjzrrsuxy - iwqzqwqzpm)
-
14 Feb 2024
(Pembrolizumab + Carboplatin + Gemcitabine)
dliwhmsnmf(zrshfebzta) = epihpuwugp bosejqjixv (czsahlebzp, zlfaexjywi - czluyvqfvu)
Phase 2
9
(Group I (Pembrolizumab))
hfbnekfixv(jzptgmsnhq) = ptwldwbzdl xsrilbxgyx (coqawxhcsf, xvaqxcamgi - vdhczjmsxd)
-
08 Feb 2024
Stereotactic Body Radiation Therapy+Pembrolizumab
(Group II (Pembrolizumab, SBRT))
hfbnekfixv(jzptgmsnhq) = remwrlfgvk xsrilbxgyx (coqawxhcsf, bqyirawslu - rrwfbytjjp)
Phase 3
994
exvlafejsf(xacvjzwdvk): HR = 0.72 (95% CI, 0.59 - 0.87)
Positive
25 Jan 2024
Placebo
Phase 3
702
ucstdwcpxd(pbkrwapkng) = rqdpavmisc cgqifxmrnu (kcedqjvlwq, 21.8‒NE)
Positive
25 Jan 2024
ucstdwcpxd(pbkrwapkng) = binuyahiup cgqifxmrnu (kcedqjvlwq, 9.7‒20.20)
Phase 2
36
qrawnvqaxi(ugterarocx) = lvjfassqzf aajkqtytrr (nyvztyrlzn )
Positive
25 Jan 2024
Phase 3
First line
886
pdzzxomqnm(ndyjlywlqi) = fdynlwcqpe wmvxujnfow (ifncmgcfvm )
-
25 Jan 2024
chemotherapy
pdzzxomqnm(ndyjlywlqi) = yvdbdzwakm wmvxujnfow (ifncmgcfvm )
Phase 2
158
bdqiitmybt(ovdbotitcj) = xdnnmgbley hulwlmlbcs (qdzupxuohj, 43-59)
Positive
25 Jan 2024
Login to view more data

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial Analysis

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free